Tempest Therapeutics (TPST) Projected to Announce Earnings on Monday

Tempest Therapeutics (NASDAQ:TPST) is expected to release its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of ($0.30) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($2.25). On average, analysts expect Tempest Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tempest Therapeutics Price Performance

Shares of NASDAQ TPST opened at $0.88 on Monday. The business’s fifty day moving average price is $1.17 and its 200-day moving average price is $1.81. Tempest Therapeutics has a one year low of $0.84 and a one year high of $12.23. The stock has a market capitalization of $14.08 million, a PE ratio of -0.15 and a beta of -1.72.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on TPST shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempest Therapeutics in a report on Monday, July 13th. Zacks Research downgraded shares of Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Wall Street Zen lowered shares of Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Tempest Therapeutics currently has a consensus rating of “Reduce”.

Institutional Investors Weigh In On Tempest Therapeutics

An institutional investor recently raised its stake in Tempest Therapeutics stock. Vanguard Group Inc. raised its holdings in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 162,560 shares of the company’s stock after buying an additional 27,952 shares during the quarter. Vanguard Group Inc. owned about 3.66% of Tempest Therapeutics worth $1,671,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Company Profile

Tempest Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune?mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator?activated receptor alpha (PPAR?) and salt?inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first?in?class PPAR? antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.